Total Funding
64
48
Total FundingPost-IPO Equity raised
Growth Score
-10 pts
Heat Score
-10 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
86627
Organogenesis Inc. is a regenerative medicine company.
- Brian Grow: Chief Commercial Officer
Gary S. Gillheeney: President and Chief Executive Officer
About the Company
Organogenesis Inc. is a regenerative medicine company with the unique skill set to take complex, living therapies from research and development (R&D), through manufacturing, to successful commercialization to reach patients today. As a pioneer in the field of regenerative medicine, Organogenesis received the first FDA approval of a living,
allogeneic, cell based product (Apligraf®, approved for the treatment of venous leg ulcers). Apligraf is now the leading regenerative medicine product in the world, with two FDA-approved indications. In 2012 we received an FDA approval for GINTUIT™, a living, human cell-based product that represents a new therapeutic class in dentistry.
